- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03476993
Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis
Open-label Non-comparative Study to Evaluate the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis
Study Overview
Detailed Description
This is an open-label proof-of-concept phase 2A study. The aim of the study is to evaluate the efficacy and safety of BCD-085 in combination with ursodeoxycholic acid in patients with primary biliary cholangitis (PBC) with compensated liver function with an inadequate (suboptimal) response to ursodeoxycholic acid.
In this study the inadequate (suboptimal) response to ursodeoxycholic acid (UDCA) is defined as screening alkaline phosphatase (ALP) level > 1.67 ULN (the upper limit of normal) despite treatment with UDCA in stable dose for at least 6 months before signing the ICF.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation
- State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University
-
Saint Petersburg, Russian Federation
- North-Western state Medical University named after I.I. Mechnikov
-
Smolensk, Russian Federation
- Smolensk State Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Singed informed consent form (ICF)
- Men and women, age 18 - 80 years at the time of signing the ICF
Established diagnosis of PBC with following criteria (according to EASL 2017 guidelines):
- documented ALP elevation
- documented АМА ≥ 1:40 or PBC-specific ANА (anti-sp100/anti-gp210).
- Suboptimal response to ursodeoxycholic acid (UDCA) taken in stable dose for at least 6 months before signing ICF with screening alkaline phosphatase (ALP) level > 1.67 ULN (the upper limit of normal)
- Fertile patients and their partners agree to use barrier contraception throughout the study and 4 weeks after its completion.
Exclusion Criteria:
- History of gastrointestinal bleeding, hepatic encephalopathy or ascites requiring treatment with diuretics.
- MELD ≥ 15, history of liver transplantation, staying in the Liver Transplant Waiting List.
- Established diagnosis of hepatocellular carcinoma (HCC), hepatorenal syndrome.
- Direct bilirubin > 1.0 mg/dL at screening.
- Documented diagnosis: nonalcoholic steatohepatitis, autoimmune hepatitis, primary sclerosing cholangitis, alcoholic liver disease, Gilbert's syndrome, Wilson disease, hemochromatosis, alfa-1-antitrypsin deficiency.
- HIV, hepatitis B, hepatitis C or syphilis.
- Use of colchicine, methotrexate, azathioprine or systemic corticosteroids within 3 months before signing the ICF.
- Previous use of monoclonal antibodies targeting IL17 or its receptor.
- Vaccination with live or attenuated vaccines within 8 weeks before signing the ICF.
- Any active systemic infection or recurrent infection at screening or 30 days before signing the ICF.
- Established diagnosis of chronic disease (e.g. sepsis, invasive mycosis, histoplasmosis etc.) that may increase the risk of infectious adverse events during the study.
- Severe infections (including those that required hospitalization or parenteral antibacterial/antimycotic/antiprotozoal treatment) within 6 months before signing the ICF
- Established diagnosis of herpes zoster infection (or history of herpes zoster infection).
- latent tuberculosis infection (positive results of the Diaskintest or QuantiFERON test, or T-spot).
- Concurrent diseases at screening that may increase the risk of adverse events during the study or affect the evaluation of PBC symptoms (mask, enhance or alter the symptoms of PBC, or cause clinical or laboratory signs/symptoms similar to those of PBC)
- Known allergy or intolerance to monoclonal antibody drugs (murine, chimeric, humanized, or human) or any other components of BCD-085.
- Pregnancy, breastfeeding or planning of pregnancy during the study.
- Any psychiatric conditions including severe depressive disorders and/or any history of suicidal thoughts or suicidal attempts that may constitute the excessive risk for the patient or that may affect the patient's ability to follow the protocol.
- Alcohol or substance abuse.
- Participation in other clinical trials within less than 90 days before signing the ICF.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BCD-085
All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
|
All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect.
All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients with alkaline phosphatase (ALP) decrease > 40% from Baseline (day 1 week 0) or with normal ALP level (Barcelona criteria) after 24 weeks of treatment with BCD-085 in combination with UDCA.
Time Frame: week 24
|
Biochemical response is defined as ALP decrease > 40% from Baseline or normalisation of ALP level (Barcelona criteria).
|
week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marina Maevskaya, State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCD-085-6
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis, Biliary
-
University Health Network, TorontoUnknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
CymaBay Therapeutics, Inc.TerminatedPrimary Biliary Cirrhosis (PBC)Germany, United States, Canada, United Kingdom, Poland
-
University Health Network, TorontoUnknownLiver Cirrhosis, Biliary | Biliary Cirrhosis, PrimaryCanada
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
Xijing Hospital of Digestive DiseasesRecruitingPrimary Biliary CirrhosisChina
-
Intercept PharmaceuticalsCompletedLiver Cirrhosis, BiliaryUnited States, France, Germany, Spain, United Kingdom, Canada, Austria
-
Dr. Falk Pharma GmbHCompletedPrimary Biliary CirrhosisGermany
-
Instituto Nacional de Ciencias Medicas y Nutricion...UnknownPrimary Biliary CirrhosisMexico
-
University of FloridaShionogi Inc.; The PBCers OrganizationCompleted
Clinical Trials on BCD-085
-
BiocadCompleted
-
BiocadActive, not recruitingAnkylosing SpondylitisRussian Federation
-
BiocadCompleted
-
BiocadActive, not recruitingPsoriatic ArthritisRussian Federation, Belarus
-
BiocadCompleted
-
Kechow Pharma, Inc.Completed
-
Shanghai Kechow Pharma, Inc.Completed
-
Idorsia Pharmaceuticals Ltd.CompletedRenal ImpairmentGermany